Dana Investment Advisors Inc. Increases Stake in LivaNova PLC $LIVN

Dana Investment Advisors Inc. lifted its stake in LivaNova PLC (NASDAQ:LIVN) by 46.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 31,118 shares of the company’s stock after acquiring an additional 9,881 shares during the period. Dana Investment Advisors Inc.’s holdings in LivaNova were worth $1,915,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of LIVN. State of Wyoming purchased a new position in shares of LivaNova in the 2nd quarter valued at approximately $31,000. EverSource Wealth Advisors LLC raised its position in shares of LivaNova by 998.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the last quarter. Quarry LP purchased a new position in shares of LivaNova in the 3rd quarter valued at approximately $36,000. UMB Bank n.a. raised its position in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after purchasing an additional 306 shares during the last quarter. Finally, Johnson Financial Group Inc. purchased a new position in shares of LivaNova in the 3rd quarter valued at approximately $63,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $70.00 on Monday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $73.30. The company has a 50 day simple moving average of $64.25 and a two-hundred day simple moving average of $62.86. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of 35.90 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. During the same period in the previous year, the business posted $0.88 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts predict that LivaNova PLC will post 3.72 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently commented on LIVN. Mizuho increased their price objective on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research report on Wednesday, February 25th. Robert W. Baird decreased their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, Needham & Company LLC lifted their price objective on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $77.22.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.